Clinical Usefulness of HLA-B∗58:01 Genotyping in Gouty Arthritis

Clinical Usefulness of HLA-B∗58:01 Genotyping in Gouty Arthritis

Allopurinol is an effective urate lowering agent but may lead to rare but life-threatening severe cutaneous adverse reactions (SCAR). Genetic predisposition, age, sex, renal function, dosage and concomitant diuretic use are known risk factors of allopurinol related SCAR. Among these factors, HLA-B∗5...

Full description

Bibliographic Details
Main Authors:	Carrel Ka Lung Yu, Chi Chiu Mok
Format:	Article
Language:	English
Published:	World Scientific Publishing 2019-07-01
Series:	Journal of Clinical Rheumatology and Immunology
Subjects:	hla-b∗58:01 allopurinol hypersensitivity severe cutaneous adverse reactions cost-effectiveness genetic screening
Online Access:	http://www.worldscientific.com/doi/epdf/10.1142/S2661341719300027

Similar Items

Clinical evaluation of a substitute of HLA-B*58:01 in different Chinese ethnic groups
by: Xinju Zhang, et al.
Published: (2018-08-01)

A Novel Allele-Specific PCR Protocol for the Detection of the HLA-C*03:02 Allele, a Pharmacogenetic Marker, in Vietnamese Kinh People
by: Pham TTH, et al.
Published: (2021-02-01)

Development of a HLA-B*58:01 Allele Screening System for Allopurinol-Induced Severe Cutaneous Adverse Reactions Detection
by: Kok Beng Gan, et al.
Published: (2020-01-01)

Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines
by: Lisanne E. N. Manson, et al.
Published: (2020-09-01)

Predominant HLA Alleles and Haplotypes in Mild Adverse Drug Reactions Caused by Allopurinol in Vietnamese Patients with Gout
by: Chu Van Son, et al.
Published: (2021-09-01)

HLA-B*58:01 for allopurinol-induced cutaneous adverse drug reactions: Implication for clinical interpretation in Thailand
by: Chonlaphat Sukasem, et al.
Published: (2016-07-01)

HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients
by: Patompong Satapornpong, et al.
Published: (2021-05-01)

Risk factors for cutaneous reactions to allopurinol in Kinh Vietnamese: results from a case-control study
by: Minh Duc Do, et al.
Published: (2020-08-01)

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
by: Catherine Butkus Small, et al.
Published: (2017-04-01)

The HLA-A*31:01 allele: influence on carbamazepine treatment
by: Yip VLM, et al.
Published: (2017-01-01)

Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated Peptides
by: Montserrat Puig, et al.
Published: (2021-02-01)

Prevalence of HLA-B*57:01 allele in HIV-infected patients in a university hospital in Tehran
by: Mahboobeh Haji-Abdolbaghi, et al.
Published: (2014-04-01)

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study
by: Karam Mounzer, et al.
Published: (2019-01-01)

GOUTY ARTHRITIS – MODERN VIEW OF THE PROBLEM
by: V. I. Mazurov, et al.
Published: (2017-11-01)

Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population
by: Napatrupron Koomdee, et al.
Published: (2017-11-01)

Association Between HLA Genotype and Cutaneous Adverse Reactions to Antiepileptic Drugs Among Epilepsy Patients in Northwest China
by: Xu Wang, et al.
Published: (2019-01-01)

Subacute Thyroiditis is Associated with <i>HLA-B*18:01</i>, -<i>DRB1*01</i> and -<i>C*04:01</i>—The Significance of the New Molecular Background
by: Magdalena Stasiak, et al.
Published: (2020-02-01)

The current treatment strategy for gouty arthritis
by: M. S. Petrova, et al.
Published: (2018-09-01)

HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
by: Ernesto Martínez Buitrago, et al.
Published: (2019-09-01)

Quality of treatment in gouty patients considering EULAR recommendations
by: Radak-Perović Marija, et al.
Published: (2012-01-01)

Sonographic Pattern of Subacute Thyroiditis Is HLA-Dependent
by: Magdalena Stasiak, et al.
Published: (2019-01-01)

Association of <it>HLA-B*5801 </it>allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis
by: Lohitnavy Manupat, et al.
Published: (2011-09-01)

Drug Allergy: Delayed Cutaneous Hypersensitivity Reactions to Drugs
by: Rose L. Hamm
Published: (2016-08-01)

Interaction of Nevirapine with the Peptide Binding Groove of HLA-DRB1*01:01 and Its Effect on the Conformation of HLA-Peptide Complex
by: Makoto Hirasawa, et al.
Published: (2018-06-01)

Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions
by: Chih-Jung Chang, et al.
Published: (2020-07-01)

The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity
by: Gwendolin S. Simper, et al.
Published: (2019-10-01)

Clinical Profile of Adverse Cutaenous Drug Reactions in Patients with Human Immunodeficiency Virus
by: Puteri Nabilah Maharani, et al.
Published: (2020-12-01)

Comparative evaluation of uricodepressants allopurinol and febuxostat in gouty nephropathy. Message 2. Еxperimental study
by: O.V. Sinyachenko, et al.
Published: (2018-04-01)

Drug reaction with eosinophilia and systemic symptoms: A drug-induced hypersensitivity syndrome with variable clinical features
by: Yi-Chun Chen, et al.
Published: (2013-12-01)

Allopurinol-induced Severe Hypersensitivity with Acute Renal Failure
by: I-Hung Chen
Published: (2005-05-01)

Adverse drug reactions triggered by the common HLA-B*57:01 variant: virtual screening of DrugBank using 3D molecular docking
by: George Van Den Driessche, et al.
Published: (2018-01-01)

HLA-B*13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity?
by: Fu-Li Min, et al.
Published: (2019-06-01)

Genetic Determinants in <i>HLA</i> and Cytochrome P450 Genes in the Risk of Aromatic Antiepileptic-Induced Severe Cutaneous Adverse Reactions
by: Ali Fadhel Ahmed, et al.
Published: (2021-05-01)

Comparative evaluation of uricodepressants allopurinol and febuxostat in gouty nephropathy. Message 1. Сlinical study
by: D.D. Ivanov, et al.
Published: (2018-04-01)

Corrigendum: Dose Dependent Antimicrobial Cellular Cytotoxicity—Implications for ex vivo Diagnostics
by: Ana Copaescu, et al.
Published: (2021-09-01)

Antibiotic hypersensitivity and adverse reactions: management and implications in clinical practice
by: Anthony Jourdan, et al.
Published: (2020-01-01)

Effect of allopurinol combined with Tongfengding capsule on inflammatory factors, hepatorenal functions and related indicators in gouty patients
by: Li Tang
Published: (2016-11-01)

Association of <i>HLA-B*51:01, HLA-B*55:01</i>, <i>CYP2C9*3,</i> and Phenytoin-Induced Cutaneous Adverse Drug Reactions in the South Indian Tamil Population
by: Shobana John, et al.
Published: (2021-07-01)

Jämförelse mellan två analyskit för typning av det humana leukocytantigenet HLA-B*57
by: Håkansson, Cornelia
Published: (2017)

Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa
by: Malewe Kolou, et al.
Published: (2021-07-01)